The FDA Just Asked the World How to Regulate AI That Writes Its Own Medical Decisions

In August 2026, the US FDA did something it doesn’t normally do: it published a discussion paper asking the public how it should regulate a category of medical AI that barely exists in deployed form yet — generative and “agentic” AI systems that don’t just assist a doctor’s judgment, but can generate their own medical outputs or take sequential actions with real clinical consequence. The comment window (docket FDA-2026-N-7874) closed on October 19, 2026, with formal responses filed by groups including the Radiological Society of North America (RSNA), which represents over 53,000 radiologists.

This isn’t a story about a specific AI product being approved or rejected. It’s the regulator trying to figure out the rulebook before the products fully arrive — which is a genuinely unusual sequence, and worth understanding if you’re going to encounter AI-driven healthcare tools in the next few years, in India or anywhere else.

What “Generative” or “Agentic” AI Medical Device Actually Means

Most AI already cleared by regulators (including in radiology, where AI-assisted scan reading is relatively mature) works in a narrow, predictable way: it looks at an image or a dataset and outputs a specific, bounded result — flag this scan for review, calculate this risk score. A radiologist or doctor remains the one making the actual decision.

“Generative” AI in this context means something that can produce novel content — a draft diagnosis narrative, a treatment suggestion phrased in open language, not just a number. “Agentic” goes further: an AI system that can take a sequence of actions on its own — for example, drafting a differential diagnosis, pulling additional data, and refining its own output across multiple steps — closer to acting like a junior clinician than a calculator. Neither category has many fully deployed, FDA-cleared examples yet; the discussion paper is explicitly about preparing the regulatory framework ahead of that wave, not reacting to one that’s already here.

What Radiologists Actually Told the FDA

RSNA’s formal comment, representing a genuinely large slice of the specialty most likely to be affected first, raised a tension that’s easy to state and hard to resolve: AI that augments a radiologist’s judgment (a second pair of eyes, faster triage) is categorically different from AI that could functionally replace parts of that judgment, and the regulatory bar should reflect that difference — not treat every generative/agentic tool as one undifferentiated risk category. The US Chamber of Commerce’s filing, from the industry side, pushed for regulatory clarity and predictability so companies can actually build toward a known standard rather than guessing.

Neither side is arguing against the technology existing — the real debate is about where the line sits between “tool that helps a licensed professional decide” and “system making a clinical decision a patient’s care depends on,” and how much independent verification that second category needs before it reaches a patient.

What This Means for Patients, Including in India

FDA rulemaking doesn’t directly govern devices sold in India, but it matters here for a practical reason: major AI-diagnostic tools built for global markets, including ones that eventually reach Indian hospitals and diagnostic chains, are frequently developed and first-cleared against FDA or equivalent frameworks before wider rollout. How the US settles this question shapes what gets built, and how cautiously, well before it shows up on an Indian clinic’s imaging software.

The practical takeaway for now isn’t alarm — it’s a reasonable habit: when an AI tool is part of your care (reading a scan, flagging a risk, suggesting a next step), it’s fair to ask whether a licensed clinician is reviewing that output before it affects your treatment, not assume the AI’s suggestion is the final word. That distinction — AI assisting a professional’s judgment versus AI substituting for it — is exactly the one regulators are still actively working out.

Frequently Asked Questions

Is there an AI system already making medical decisions without a doctor involved?
Not in any widely deployed, FDA-cleared form as of this writing — this discussion paper is specifically about building the regulatory framework ahead of that category maturing, not describing something already in common use.

Does this affect AI tools already used in Indian hospitals, like AI-assisted scan reading?
Most currently deployed medical AI (including in India) falls into the narrower, already-regulated category — bounded outputs reviewed by a clinician — not the generative/agentic category this specific FDA discussion paper addresses.

Where can I read the actual FDA document?
The discussion paper and public comments are posted on regulations.gov under docket FDA-2026-N-7874, publicly accessible to anyone, including the RSNA and Chamber of Commerce filings referenced here.

Explore the Wider Medimadad Ecosystem

This article sits in Medimadad’s AI-in-healthcare coverage — the regulatory and policy side of a technology this site has also covered from the clinical-accuracy and patient-experience angles below. For the human side of how people are actually using AI for health decisions and connection, Medimadad Mind & Meanings explores related territory.

Further Reading on Medimadad

• AI Diagnostic Accuracy vs. Doctors: What the Real Comparisons Show
• AI Is Already Reading Your Scans: What Patients Should Know
• FDA Clears an AI Tool to Detect Heart Disease Before Symptoms Appear